Technology | June 11, 2012

Mevion Medical Gains FDA Clearance for the Mevion S250 Proton Therapy System

Mevion S250 patented technology significantly reduces the cost of implementing and operating proton therapy centers.

June 11, 2012 — Mevion Medical Systems, Inc., a radiation therapy company dedicated to advancing the treatment of cancer, announced that it has received U.S. Food and Drug Administration (FDA)  510(k) clearance for its Mevion S250 Proton Therapy System. The Mevion S250 is a first-of-its-kind proton therapy system that provides the same precise, non-invasive treatment advantages and capabilities of complex, large, and costly proton therapy systems but with higher patient throughput, a significantly reduced footprint, improved reliability, and lower implementation and operational costs.  The Mevion S250 delivers precise and intense proton beams that physicians can use to treat tumors and lesions or any other condition where radiotherapy is indicated. 

The broad adoption of proton therapy has been greatly limited by the enormous cost, large footprint, and technical complexity of traditional proton therapy systems. Powered by a patented TriNiobium Core, the Mevion S250 proton therapy system redefines the economics, availability, and the future direction of proton therapy, by bringing the management and operation of proton therapy to levels similar to modern X-ray radiation therapy devices. 

This clearance enables users of the Mevion S250 to immediately treat patients upon completion of their system installation. The first installation of the Mevion S250 will soon be completed at the Kling Center for Proton Therapy at Barnes Jewish Hospital at Washington University in St. Louis, Mo.

Mevion will be delivering and installing more than a dozen Mevion S250 proton therapy systems worldwide within the next two years, making it one of the leading providers of proton therapy systems. Mevion S250 installations are also underway at Robert Wood Johnson University Hospital in New Jersey and Oklahoma University in Oklahoma. Additional sites in Florida and California will follow these installations.

Earlier this year, the Mevion S250 received CE certification, which gives Mevion the ability to market, sell, import, and install proton therapy systems in the European Union and other regions where the CE Marking is recognized.

Related Content

Raysearch RayStation
Feature | Radiation Therapy | June 05, 2018 | By Melinda Taschetta-Millane
Treatment planning systems are at the heart of r...
Lung Decision Precision
News | Lung Cancer | June 04, 2018
For smokers and former smokers, the threat of lung cancer always lurks in the shadows.
Beaumont Researchers Invent New Mode of Proton Treatment for Lung Cancer
News | Proton Therapy | May 31, 2018
Members of Beaumont Health’s proton therapy team presented research on a new treatment for patients with lung cancer at...
More Than 60 Percent of Patients Seeking Proton Therapy Initially Denied Coverage
News | Proton Therapy | May 25, 2018
The Alliance for Proton Therapy Access has released a national report revealing the heavy emotional and financial...
Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Metal artifact reduction led to a 20 percent increase in the planning target volume (PTV) in this prostate cancer case from Henry Ford Health System. The volume of the healthy bladder tissue to be spared was also reduced by 4 percent.

Feature | Computed Tomography (CT) | May 03, 2018 | By Jeff Zagoudis
Computed tomography (CT) has long been the standard of care for imaging to plan radiation therapy (RT) treatments. 
MedStar Georgetown Conducts World's First Hyperscan Proton Therapy Treatment
News | Proton Therapy | April 27, 2018
For the first time, cancer patients in the Washington, D.C. metropolitan region have access to proton therapy, now...
First Patient Treated on Mevion's S250i Proton Therapy System
News | Proton Therapy | April 05, 2018
Mevion Medical Systems announced the treatment of the first patient in the world on the Mevion S250i Proton Therapy...
MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

MEDraysintell released a report in January revising its projection for the number of proton therapy centers worldwide by 2030 down from 1,200 to 900. The company said that more than 50 proton therapy treatment rooms would need to be opened every year from 2018 to 2030 to hit the original projection of 1,200.

Feature | Proton Therapy | March 06, 2018 | By Jeff Zagoudis
Proton therapy has experienced major growth in the last decade, but that growth seems to have slowed slightly in recent...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
RayStation Selected for India’s First Proton Center
News | Proton Therapy | February 01, 2018
February 1, 2018 – Apollo Hospitals, Asia´s foremost integrated healthcare provider, has selected RayStation for a ne
Overlay Init